Literature DB >> 12786824

Human placental amnion is a novel substrate for detecting autoantibodies in autoimmune bullous diseases by immunoblotting.

N Oyama1, B S Bhogal, P Carrington, M J Gratian, M M Black.   

Abstract

BACKGROUND: Identification of antigens by immunoblotting techniques, using epidermal and dermal extracts, is regarded as essential for making a definitive diagnosis in autoimmune bullous diseases (AIBDs). These procedures involve epidermal-dermal separation for subsequent protein extraction, which may result in partial loss of some antigenic polypeptides and changes in the conformational epitopes targeted by autoantibodies in AIBDs. It may therefore be necessary to use different substrates for consistent results. Objectives To evaluate the usefulness of human placental amnion extract as a substrate for immunoblotting in the diagnosis of AIBDs.
METHODS: We checked the structural components of the desmosomes and basement membrane zone (BMZ) of amnion by electron microscopy. Using immunofluorescence and immunoblotting techniques, we tested the amnion immunoreactivity with antibodies to desmosomal and BMZ proteins, and with sera from 76 patients with AIBDs including pemphigus vulgaris, pemphigus foliaceus, bullous pemphigoid (BP), pemphigoid gestationis, linear IgA bullous dermatosis, epidermolysis bullosa acquisita, paraneoplastic pemphigus and mucous membrane pemphigoid.
RESULTS: The desmosomes and BMZ of the amnion tissue were ultrastructurally similar to those in skin. Antigen mapping confirmed that amnion contains all the proteins that were recognized by a panel of monoclonal and polyclonal antibodies. Immunoblotting showed that the antibodies clearly detected bands corresponding to desmogleins 1 and 3, desmocollins 1 and 2, desmoplakins 1 and 2, three subunits (alpha3, beta3 and gamma2) of laminin 5, BP antigens 1 and 2, the 97-kDa LAD antigen and type VII collagen. In addition, most of the patient sera (82%) reacted exclusively with their respective antigens.
CONCLUSIONS: Harvesting proteins from amnion does not require epidermal-dermal separation, and a sufficient yield of desmosomal and hemidesmosomal proteins can be obtained. Therefore, amnion may be a more reliable source of substrate than skin samples for immunoblot analysis of AIBDs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12786824     DOI: 10.1046/j.1365-2133.2003.05316.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

1.  The role of labeled cell therapy with and without scaffold in early excision burn wounds in a rat animal model.

Authors:  Seyedeh Sara Hashemi; Mohammad Reza Pourfath; Amin Derakhshanfar; Abbas Behzad-Behbahani; Javad Moayedi
Journal:  Iran J Basic Med Sci       Date:  2020-05       Impact factor: 2.699

2.  Comparison of Two Diagnostic Assays for Anti-Laminin 332 Mucous Membrane Pemphigoid.

Authors:  Stephanie Goletz; Federica Giurdanella; Maike M Holtsche; Miranda Nijenhuis; Barbara Horvath; Gilles F H Diercks; Detlef Zillikens; Takashi Hashimoto; Enno Schmidt; Hendri H Pas
Journal:  Front Immunol       Date:  2021-11-25       Impact factor: 7.561

3.  Analysis of Anti-desmoglein 1 Autoantibodies in 68 Healthy Mother/Neonate Pairs from a Highly Endemic Region of Fogo Selvagem in Brazil.

Authors:  Julio Hilario-Vargas; Irineu B Vitorio; Christopher Stamey; Donna A Culton; Phillip Prisayanh; Evandro A Rivitti; Valeria Aoki; Gunter Hans Filho; Vandir Dos Santos; Bahjat Qaqish; Luis A Diaz
Journal:  J Clin Exp Dermatol Res       Date:  2014-02-24

Review 4.  Diagnosis of Autoimmune Blistering Diseases.

Authors:  Mareike Witte; Detlef Zillikens; Enno Schmidt
Journal:  Front Med (Lausanne)       Date:  2018-11-02

5.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.